Drug Profile
Research programme: vaccines and inhaled therapeutics - GlaxoSmithKline/Liquidia Technologies
Latest Information Update: 04 Jul 2019
Price :
$50
*
At a glance
- Originator GlaxoSmithKline; Liquidia Technologies
- Developer GSK; Liquidia Technologies
- Class Vaccines
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 26 Jun 2019 Liquidia Technologies amends its collaboration agreement with GlaxoSmithKline to develop and commercialise inhaled therapeutics
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in USA (Inhalation)
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in USA (Parenteral)